Travere Therapeutics (TVTX) Other Non-Current Liabilities (2011 - 2026)

Travere Therapeutics has reported Other Non-Current Liabilities for 16 years, with the latest figure at $9.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 28.92% year-over-year to $9.4 million; the trailing twelve-month figure through Mar 2026 stood at $9.4 million (up 28.92% YoY), and the FY2025 full-year result was $7.6 million, up 11.85% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $9.4 million, up from $7.6 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $75.7 million in Q2 2022, with the low at $5.9 million in Q3 2025.
• Historically, Other Non-Current Liabilities has averaged $13.8 million across 5 years, with a median of $9.3 million in 2022.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 88.46% — and 2024, when it soared 94.34%.
• Travere Therapeutics' Other Non-Current Liabilities stood at $9.4 million in 2022, then gained by 9.96% to $10.3 million in 2023, then tumbled by 34.15% to $6.8 million in 2024, then gained by 11.85% to $7.6 million in 2025, then advanced by 23.38% to $9.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $9.4 million (Q1 2026), $7.6 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.